<DOC>
	<DOCNO>NCT02195804</DOCNO>
	<brief_summary>The objective study establish relative bioavailability ( BA ) two different ranitidine hydrochloride 150 mg ODT formulation comparison current , counter ( OTC ) ranitidine hydrochloride ( Maximum Strength ZANTAC 150® ) formulation follow oral single dose administration fast healthy male volunteer</brief_summary>
	<brief_title>Bioavailability Study Ranitidine Hydrochloride ( Maximum Strength ZANTAC 150® ) Compared Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet ( ODT ) Fasting , Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Healthy male subject base : complete medical history , include physical examination , vital sign ( pulse rate ( PR ) , systolic &amp; diastolic blood pressure ( BP ) body temperature ) , 12lead electrocardiogram ( ECG ) clinical laboratory test Age ≥ 18 Age ≤ 60 year BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) body weight ≥ 55 kg Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any clinically relevant abnormality find screen physical examination ( include BP , PR ) ECG opinion investigator patient suitable study Any evidence acute chronic gastrointestinal condition relevant concomitant medical disease History acute porphyria History peptic ulcer disease Heartburn require treatment ( OTC prescription medicine ) within last 30 day History surgery gastrointestinal tract surgery ( except appendectomy cholecystectomy ) History relevant allergy / hypersensitivity ( include allergy H2 inhibitor ) drug class , ranitidine hydrochloride excipients ) Intake prescription overthecounter ( OTC ) drug long halflife ( &gt; 24 hour ) within least 2 week less 10 halflives respective drug prior administration trial Participation another trial investigational drug within 30 day prior administration trial Inability refrain alcohol use 48 hour prior drug administration end study visit treatment period History alcohol ( 60 g/day ) drug abuse Blood donation ( 100 mL within four week prior administration trial ) Any laboratory value outside reference range clinical relevance determine investigator Inability comply dietary regimen trial site Subjects test positive upon drug screen Subjects consume caffeine xanthinecontaining drink food ( coffee , tea , cola , energy drink , chocolate , etc . ) 48 hour prior study drug administration Subjects consume citrus fruit juice , ( particular grapefruit Seville orange , sour bitter orange ) , product contain St. John 's wort ( Hypericum perforatum ) allow 7 day prior dose administration Excessive physical activity exercise ( organize sport ) trial period</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>